Mary Brown
Member
Global diagnostics leader QIAGEN has commercially launched QIAsymphony Connect, an IVD-compliant platform designed for nucleic acid extraction across mid- to high-volume clinical laboratories. Building upon the global foundation of thousands of cumulative QIAsymphony placements worldwide, the next-generation system automates sample preparation to enhance workflow consistency, boost operational productivity, and enforce rigorous process safety. As diagnostic demand expands across oncology, liquid biopsy, and infectious disease testing, the system provides automated liquid handling and magnetic bead-based purification to standardize clinical molecular workflows.
The platform allows laboratories to process up to 96 samples in four independent batches of 24, accommodating a versatile range of input sample volumes. Utilizing an optimized bead collection and elution methodology, QIAsymphony Connect delivers concentrated DNA and RNA eluates tailored for sensitive downstream applications, including digital PCR (dPCR) and next-generation sequencing (NGS). Importantly, the system maintains complete backward compatibility with existing QIAsymphony reagent kits and consumables, allowing established facility networks to upgrade their automation capabilities without extensive re-validation hurdles or operational downtime.
To streamline routine operation, the instrument features an intuitive touchscreen interface with guided workflow setup. Built-in digital connectivity—including native Laboratory Information Management System (LIMS) integration via standard HL7 protocols and QIAsphere cloud management—enables remote monitoring of system status, consumable inventories, and run progress. These digital tools help reduce manual touchpoints, lower operator training requirements, and minimize the risk of procedural errors during routine diagnostic processing.
Initial customer orders and early lab deployments demonstrate rapid market adoption as healthcare organizations seek to scale molecular diagnostic output. By unifying robust sample preparation, automated chain-of-custody tracking, and flexible digital connectivity into a standardized footprint, QIAsymphony Connect strengthens QIAGEN's comprehensive Sample to Insight portfolio for modern clinical laboratories.
Discover Health Tech Insiders for the latest advancements in medical technology and trusted strategic insights shaping the future of tech-driven healthcare transformation.
Read related news- https://healthtechinsiders.com/premier-and-hshs-partnership-expands-healthcare-care/
The platform allows laboratories to process up to 96 samples in four independent batches of 24, accommodating a versatile range of input sample volumes. Utilizing an optimized bead collection and elution methodology, QIAsymphony Connect delivers concentrated DNA and RNA eluates tailored for sensitive downstream applications, including digital PCR (dPCR) and next-generation sequencing (NGS). Importantly, the system maintains complete backward compatibility with existing QIAsymphony reagent kits and consumables, allowing established facility networks to upgrade their automation capabilities without extensive re-validation hurdles or operational downtime.
End-to-End Sample Traceability and Digital Integration
A major focus of the QIAsymphony Connect architecture is supporting regulatory compliance and sample integrity in busy diagnostic environments. Integrated smart cameras automatically scan 1D and 2D barcodes on primary sample tubes, reagent cartridges, and final eluate containers. This automated tracking maintains a continuous chain of custody throughout lysis, binding, washing, and elution phases, generating complete audit trails for every run.To streamline routine operation, the instrument features an intuitive touchscreen interface with guided workflow setup. Built-in digital connectivity—including native Laboratory Information Management System (LIMS) integration via standard HL7 protocols and QIAsphere cloud management—enables remote monitoring of system status, consumable inventories, and run progress. These digital tools help reduce manual touchpoints, lower operator training requirements, and minimize the risk of procedural errors during routine diagnostic processing.
Expanding Precision Diagnostics and Liquid Biopsy Workflows
The commercial rollout directly addresses the increasing clinical reliance on circulating cell-free DNA (cfDNA) and liquid biopsy assays. Isolating high-purity nucleic acids from challenging or low-input clinical specimens—such as blood plasma, buffy coat, and tissue samples—is essential for accurate minimal residual disease (MRD) monitoring and target mutation profiling. QIAsymphony Connect accelerates these applications by delivering cfDNA extraction protocols up to 25% faster while achieving higher nucleic acid yields with low elution volumes.Initial customer orders and early lab deployments demonstrate rapid market adoption as healthcare organizations seek to scale molecular diagnostic output. By unifying robust sample preparation, automated chain-of-custody tracking, and flexible digital connectivity into a standardized footprint, QIAsymphony Connect strengthens QIAGEN's comprehensive Sample to Insight portfolio for modern clinical laboratories.
Discover Health Tech Insiders for the latest advancements in medical technology and trusted strategic insights shaping the future of tech-driven healthcare transformation.
Read related news- https://healthtechinsiders.com/premier-and-hshs-partnership-expands-healthcare-care/
